ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2015
MicroRNAs as Therapeutic Targets in Lung Disease: Prospects and Challenges.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Extracellular Vesicles in Allergy: From Cellular Communication to Clinical Implications.Clinical reviews in allergy & immunology · 2026Review
- MicroRNAs in long COVID: roles, diagnostic biomarker potential and detection.Human genomics · 2025Review
- Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression.International journal of molecular sciences · 2024Review
- Upregulated microRNA-125b-5p in patients with asthma-COPD overlap mediates oxidative stress and late apoptosis via targeting IL6R/TRIAP1 signaling.Respiratory research · 2024Article
- microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis.JCI insight · 2023Article
- Extracellular Vesicles as Central Mediators of COPD Pathophysiology.Annual review of physiology · 2022Review
- Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs.International immunopharmacology · 2021Review
- The role of miRNAs in alveolar epithelial cells in emphysema.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Identification of common microRNA between COPD and non-small cell lung cancer through pathway enrichment analysis.BMC genomic data · 2021Article
- miR-4456/CCL3/CCR5 Pathway in the Pathogenesis of Tight Junction Impairment in Chronic Obstructive Pulmonary Disease.Frontiers in pharmacology · 2021Article
- Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope?The EPMA journal · 2020Review
- TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression.Biochemical pharmacology · 2020Article
- Article
- Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease-A Next-Generation Sequencing-Guided Bioinformatic Approach.International journal of molecular sciences · 2019Article
- Review
- Chronic obstructive pulmonary disease: MicroRNAs and exosomes as new diagnostic and therapeutic biomarkers.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate multiple target genes providing fine-tuned coordinated expression. Growing evidence suggests that miRNAs play important roles in lung development and the pathogenesis of lung disease and that they have great potential as novel therapeutic targets for the treatment of diseases such as lung cancer, asthma, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). We have previously shown that miR-146a is a promising therapeutic target for controlling abnormal inflammatory response in COPD through a series of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.